Next Big Futures article Badgercare, a small biotech startup, has been granted a patent for its “Zofran” fertility treatment.
The drug is designed to increase sperm count by up to 75 percent, but is currently only available to pregnant women in the U.S. The company says it is working on a Phase 2b clinical trial.
“It has the potential to improve the quality of life for pregnant women and help them achieve pregnancy, by increasing sperm count and preventing pregnancy,” BadgerCo CEO, Jaron Bekkal said in a statement.
The patent application, which was filed on August 6, says the drug “has the potential of helping prevent premature pregnancy in women, which is a major cause of morbidity and mortality in the United States.”
It also claims that “the drug reduces the chance of ectopic pregnancy by 40 percent, and the chances of fertilization by up 80 percent.”
According to the patent application: “The drug is an implantable intrauterine device, which has the capacity to be inserted into a woman’s uterus.”
The company’s website says that “The Zofran is a single-use, long-acting, biologic contraceptive implantable in a woman of any age.
The implantable contraceptive implant is designed specifically to deliver the Zofrin directly into the uterine wall.
It is designed as a ‘smart’ contraception that does not require the use of the pill or other hormonal contraceptive.”
Badger said in the patent filing that its Zofrano was tested on women ages 18 to 35, who are at an increased risk for pregnancy and sexually transmitted diseases, and is expected to be available in the next few months.
Badger is based in Palo Alto, California, but has offices in New York, San Francisco and Boston.
According to its website, the company provides “a wide variety of contraceptive products and services including: birth control pills, implants, patches, patches for injection, birth control patch packs, vaginal ring and other contraceptive methods and devices.”
Its product page describes Zofras as “a contraceptive with a very high level of safety and efficacy.”
Badgers patented technology also helps the company to build a clinical trial for its ZOFRAN device.
Badgers patent was granted on July 6, and was previously filed in September 2015.